{
    "clinical_study": {
        "@rank": "72072", 
        "arm_group": {
            "arm_group_label": "Type 2 diabetes mellitus subjects initiating Kombiglyze XR", 
            "description": "Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this post-marketing surveillance is to investigate and confirm the type and\n      incidence of newly identified adverse events and any other factors affecting safety and\n      efficacy of Kombiglyze Extended release (XR) so that the regulatory authority can manage the\n      marketing approval properly"
        }, 
        "brief_title": "Korean Post-marketing Surveillance for Kombiglyze XR\u00ae", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years of age\n\n          -  Have diagnosed Type 2 diabetes mellitus (T2DM)\n\n          -  Are initiating Kombiglyze XR treatment within the approved Korean indications\n\n        Exclusion Criteria:\n\n          -  Being treated for an indication not approved for the use of Kombiglyze XR in Korea\n\n          -  Is contraindicated for the use of Kombiglyze XR as described in the Korean label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment\n        within the approved indications will be enrolled"
            }
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754142", 
            "org_study_id": "CV181-306"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 3, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": ", Site 001"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam-si, Gyeonggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "463-823"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": ", Site 002"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-907"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of known and unexpected adverse events, especially serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 days after last dose of study drug (Approximately up to 4.5 years)"
            }, 
            {
                "measure": "Incidence of adverse events under the routine drug use", 
                "safety_issue": "Yes", 
                "time_frame": "30 days after last dose of study drug (Approximately up to 4.5 years)"
            }, 
            {
                "measure": "Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24 (for patients that have a post Week 12 follow-up visit)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events (AEs)", 
                "measure": "Safety information related to factors (eg, gender, demographics etc) that may affect the safety of the drug based on incidence rates of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 4.5 years"
            }, 
            {
                "measure": "Safety information related to factors (eg, gender, demographics etc) that may affect the effectiveness of the drug based on incidence rates of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 4.5 years"
            }, 
            {
                "measure": "Safety information related to overdose, drug-to-drug interaction and laboratory abnormalities based on incidence rates of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 4.5 years"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}